Flaxseed oil supplementation decreases C-reactive protein levels in chronic hemodialysis patients
| Autor: | Marina Cargnin, Joana Raquel Nunes Lemos, Mariana Gascue Alencastro, R.C. Manfro, Anita Vieceli Konrath |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Linseed Oil medicine.medical_treatment Endocrinology Diabetes and Metabolism Anti-Inflammatory Agents Placebo Gastroenterology Body Mass Index C-reactive protein chemistry.chemical_compound High-density lipoprotein Endocrinology Double-Blind Method Renal Dialysis Internal medicine Flax medicine Humans Renal replacement therapy Aged Inflammation Nutrition and Dietetics biology business.industry Cholesterol HDL Middle Aged Eicosapentaenoic acid Dietary Fats Clinical trial chemistry Low-density lipoprotein Hemodialysis Dietary Supplements Seeds biology.protein Kidney Failure Chronic Female Flaxseed oil business Body mass index Phytotherapy Human |
| Zdroj: | Nutrition Research. 32(12):921-927 |
| ISSN: | 0271-5317 |
| DOI: | 10.1016/j.nutres.2012.08.007 |
| Popis: | Malnutrition and chronic inflammation in dialysis patients negatively impact their survival prognosis, and nutrients, such as omega-3 oils, are postulated to reduce proinflammatory response. In this randomized, double-blind, multicenter, placebo-controlled trial, we investigated the effects of flaxseed oil (FO) on the inflammatory state of patients with chronic renal failure undergoing renal replacement therapy with hemodialysis (HD). We hypothesized that FO supplementation lowers C-reactive protein (CRP) levels. One hundred sixty patients with chronic renal failure who received HD therapy of 3 dialysis units over a 3-month period in South Brazil were included. The patients received blind doses of FO (1 g twice a day) and placebo (mineral oil, 1 g twice a day) for a period of 120 days. Inflammation was observed in 89 patients (61%) at the beginning of the study. There was a correlation between CRP and the body mass index (Rs = 0.22; P = .022) and high-density lipoprotein cholesterol (Rs = −0.23; P = .032), and the CRP levels decreased significantly over time in the group that received FO compared with the control group (P < .001). During the study period, 33.3% of the FO group changed from an inflamed to a not-inflamed category, whereas only 16.9% changed in the mineral oil group (P = .04). We conclude that the administration of FO decreases the CRP levels and that inflammation in HD patients appears to be correlated to their body mass index and reduced high-density lipoprotein cholesterol levels. Studies with a larger number of patients and over a longer duration are necessary to corroborate these findings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect